174 related articles for article (PubMed ID: 28379896)
1. Spectrum of metastatic and nonmetastatic skeletal findings with dual-phase 18F-FECH PET/CT in patients with biochemical relapse of prostate cancer.
Haroon A; Syed R; Endozo R; Allie R; Freeman A; Emberton M; Bomanji J
Nucl Med Commun; 2017 May; 38(5):407-414. PubMed ID: 28379896
[TBL] [Abstract][Full Text] [Related]
2. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
[TBL] [Abstract][Full Text] [Related]
3. Pairwise comparison of 18F-FDG and 18F-FCH PET/CT in prostate cancer patients with rising PSA and known or suspected second malignancy.
How Kit N; Dugué AE; Sevin E; Allouache N; Lesaunier F; Joly F; Aide N
Nucl Med Commun; 2016 Apr; 37(4):348-55. PubMed ID: 26642435
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist
Wieser G; Popp I; Christian Rischke H; Drendel V; Grosu AL; Bartholomä M; Weber WA; Mansi R; Wetterauer U; Schultze-Seemann W; Meyer PT; Jilg CA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1463-1472. PubMed ID: 28417160
[TBL] [Abstract][Full Text] [Related]
5. Lung uptake of fluorine-18 fluoroethyl-choline PET-CT in patients with prostate cancer.
Pizzuto DA; Annunziata S; Ieria FP; Caldarella C; Isgrò MA; Lanni V; Bencivenga G; Rufini V; Giordano A
Q J Nucl Med Mol Imaging; 2019 Dec; 63(4):387-393. PubMed ID: 29345442
[TBL] [Abstract][Full Text] [Related]
6.
Haroon A; Ahmed HU; Cathcart P; Almuhaideb A; Kayani I; Dickson J; Kirkham A; Freeman A; Emberton M; Bomanji J
AJR Am J Roentgenol; 2016 Dec; 207(6):1297-1306. PubMed ID: 27611962
[TBL] [Abstract][Full Text] [Related]
7. Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer.
Witkowska-Patena E; Giżewska A; Dziuk M; Miśko J; Budzyńska A; Walęcka-Mazur A
Clin Nucl Med; 2019 Dec; 44(12):e629-e633. PubMed ID: 31689286
[TBL] [Abstract][Full Text] [Related]
8. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
9. Fluorine-18-fluoroethylcholine PET/CT in the detection of prostate cancer: a South African experience.
Vorster M; Modiselle M; Ebenhan T; Wagener C; Sello T; Zeevaart JR; Moshokwa E; Sathekge MM
Hell J Nucl Med; 2015; 18(1):53-9. PubMed ID: 25840573
[TBL] [Abstract][Full Text] [Related]
10. Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.
Ghedini P; Bossert I; Zanoni L; Ceci F; Graziani T; Castellucci P; Ambrosini V; Massari F; Nobili E; Melotti B; Musto A; Zoboli S; Antunovic L; Kirienko M; Chiti A; Mosconi C; Ardizzoni A; Golfieri R; Fanti S; Nanni C
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):751-758. PubMed ID: 29192364
[TBL] [Abstract][Full Text] [Related]
11. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.
Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Hammer J; Loidl W; Pirich C; Fogelman I; Langsteger W
Mol Imaging Biol; 2010; 12(1):98-107. PubMed ID: 19588206
[TBL] [Abstract][Full Text] [Related]
12. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.
Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Hammer J; Loidl W; Pirich C; Fogelman I; Langsteger W
Mol Imaging Biol; 2009; 11(6):446-54. PubMed ID: 19326171
[TBL] [Abstract][Full Text] [Related]
13. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Flusser G; Zuriel L; Kollender Y; Lerman H; Lievshitz G; Ron I; Mishani E
J Nucl Med; 2004 Feb; 45(2):272-8. PubMed ID: 14960647
[TBL] [Abstract][Full Text] [Related]
14. Prostate Cancer Lytic Bone Metastases Imaged With 18F-Fluorocholine PET/CT.
Alabed YZ
Clin Nucl Med; 2018 Mar; 43(3):220-221. PubMed ID: 29356739
[TBL] [Abstract][Full Text] [Related]
15. 18F-Choline PET/CT-Positive Lytic Bone Lesions in Prostate Cancer and Accidental Myeloma Detection.
Florimonte L; Orunesu E; Castellani M; Longari V; Cortelezzi A
Clin Nucl Med; 2016 May; 41(5):394-6. PubMed ID: 26825195
[TBL] [Abstract][Full Text] [Related]
16. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
Nanni C; Zanoni L; Pultrone C; Schiavina R; Brunocilla E; Lodi F; Malizia C; Ferrari M; Rigatti P; Fonti C; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1601-10. PubMed ID: 26960562
[TBL] [Abstract][Full Text] [Related]
17. (18)F-Choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer.
Kwee SA; Coel MN; Ly BH; Lim J
Ann Nucl Med; 2009 Aug; 23(6):541-8. PubMed ID: 19529978
[TBL] [Abstract][Full Text] [Related]
18. Dual-phase (18)F-fluorocholine PET/CT to detect locoregional recurrence of prostate cancer: comparison between each time point of imaging and a summation scan.
Tong AK; Zhang ZX; Zaheer S; Yan XS
Clin Imaging; 2016; 40(3):486-91. PubMed ID: 27133692
[TBL] [Abstract][Full Text] [Related]
19. 18F-choline positron emission tomography/computed tomography for the detection of prostate cancer relapse: assessment of maximum standardized uptake value correlation with prostate-specific antigen levels.
Siminiak N; Wojciechowska K; Miechowicz I; Cholewiński W; Ruchała M; Czepczyński R
Nucl Med Commun; 2019 Dec; 40(12):1263-1267. PubMed ID: 31568268
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
